Dr. Omar Nadeem, MD
Claim this profileDana Farber Cancer Institute
Expert in Plasma Cell Neoplasm
Expert in Multiple Myeloma
18 reported clinical trials
26 drugs studied
About Omar Nadeem, MD
Education:
- MD from Harvard Medical School, 2015.
- Residency in Internal Medicine at Massachusetts General Hospital, 2018.
- Fellowship in Hematology and Oncology at Dana-Farber Cancer Institute/Brigham and Women's Hospital, 2021.
Experience:
- Specializes in hematology and oncology.
- Affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Affiliated Hospitals
Clinical Trials Omar Nadeem, MD is currently running
Iberdomide + Daratumumab vs. Bortezomib
for Multiple Myeloma
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Recruiting2 awards Phase 3
Quad Therapy
for Multiple Myeloma
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
Recruiting1 award Phase 27 criteria
More about Omar Nadeem, MD
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Omar Nadeem, MD has experience with
- Dexamethasone
- Daratumumab
- Lenalidomide
- Pomalidomide
- Elotuzumab
- Iberdomide
Breakdown of trials Omar Nadeem, MD has run
Plasma Cell Neoplasm
Multiple Myeloma
Relapse
Monoclonal Gammopathy
Relapsing
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Omar Nadeem, MD specialize in?
Omar Nadeem, MD focuses on Plasma Cell Neoplasm and Multiple Myeloma. In particular, much of their work with Plasma Cell Neoplasm has involved Stage IV patients, or patients who are undergoing treatment.
Is Omar Nadeem, MD currently recruiting for clinical trials?
Yes, Omar Nadeem, MD is currently recruiting for 4 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Omar Nadeem, MD has studied deeply?
Yes, Omar Nadeem, MD has studied treatments such as Dexamethasone, Daratumumab, Lenalidomide.
What is the best way to schedule an appointment with Omar Nadeem, MD?
Apply for one of the trials that Omar Nadeem, MD is conducting.
What is the office address of Omar Nadeem, MD?
The office of Omar Nadeem, MD is located at: Dana Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.